Physician profile
Bruce C Brink
NPI 1902898190
$6,592.90
in general payments reported to CMS, 2019-2025
38 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $745 · 2021: $1,091 · 2022: $637 · 2023: $894 · 2024: $716 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,098.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,481.86 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $1,122.07 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $721.80 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $437.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $342.32 | 2019-2025 | |
| Pfizer INC. | $298.47 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $269.84 | 2019-2022 | |
| Eisai INC. | $248.31 | 2020-2025 | |
| Lilly USA, LLC | $193.71 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Glaxosmithkline, LLC. | $144.24 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $140.89 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $139.37 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.02 | 2019-2022 | |
| Dexcom, INC. | $106.74 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.47 | 2020-2025 | Jardiance |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Brink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.